Markku Tapani Jalkanen
Founder at FARON PHARMACEUTICALS OY
Net worth: 5 M $ as of 30/05/2024
Markku Tapani Jalkanen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FARON PHARMACEUTICALS OY | Director/Board Member | 31/12/2002 | - |
| Founder | 31/12/2002 | - | |
| Chief Executive Officer | 31/12/2006 | 30/04/2024 | |
Inveni Capital Oy
 Inveni Capital Oy Investment ManagersFinance Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki. | Private Equity Investor | 31/12/2013 | - |
| Faron Ventures Oy | Director/Board Member | - | - |
Career history of Markku Tapani Jalkanen
Former positions of Markku Tapani Jalkanen
| Companies | Position | Start | End |
|---|---|---|---|
| BIOTIE THERAPIES CORP | Chief Executive Officer | 31/05/1996 | 31/12/2001 |
| Founder | 31/05/1992 | 31/12/2001 | |
| President | 31/05/1996 | 31/12/2001 | |
| University of Turku | Corporate Officer/Principal | 31/12/1991 | - |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Director/Board Member | - | - |
Medeia Therapeutics Oy
 Medeia Therapeutics Oy Miscellaneous Commercial ServicesCommercial Services Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^ | Director/Board Member | 08/12/2009 | 08/12/2009 |
| Chairman | 08/12/2009 | - | |
Lx Therapies Oy
 Lx Therapies Oy Pharmaceuticals: MajorHealth Technology Lx Therapies Oy provides drug discovery solutions for cancer treatment. It focused on developing gene mediated therapies for the prevention and treatment of diseases of lymphatic vasculature. Its therapies are used for the treatment of breast cancer related lymphoedema. The company was founded in 2008 and is headquartered in Helsinki, Finland. | Chairman | - | - |
Training of Markku Tapani Jalkanen
| University of Turku | Doctorate Degree |
| University of Kuopio | Graduate Degree |
Statistics
International
| Finland | 9 |
| Germany | 2 |
Operational
| Director/Board Member | 4 |
| Chairman | 2 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FARON PHARMACEUTICALS OY | Health Technology |
| Private companies | 6 |
|---|---|
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Inveni Capital Oy
Inveni Capital Oy Investment ManagersFinance Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki. | Finance |
Medeia Therapeutics Oy
Medeia Therapeutics Oy Miscellaneous Commercial ServicesCommercial Services Medeia Therapeutics Oy operates a biotechnology company which discovers and develops new therapeutic approaches for diseases with unmet medical needs. It focuses areas which include the discovery, preclinical research and early development of novel therapeutics. The company’s research and development programs develops small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Medeia Therapeutics was founded by Jari Eerik Koistinaho in 2006 and is headquartered in Kuopio, Finland.^ ^ | Commercial Services |
Lx Therapies Oy
Lx Therapies Oy Pharmaceuticals: MajorHealth Technology Lx Therapies Oy provides drug discovery solutions for cancer treatment. It focused on developing gene mediated therapies for the prevention and treatment of diseases of lymphatic vasculature. Its therapies are used for the treatment of breast cancer related lymphoedema. The company was founded in 2008 and is headquartered in Helsinki, Finland. | Health Technology |
| Faron Ventures Oy | |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Commercial Services |